$768 Million is the total value of Novo Holdings A/S's 17 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 19.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INGN | INOGEN INC | $337,540,000 | -0.3% | 3,549,320 | 0.0% | 43.93% | +8.4% | |
| XLRN | ACCELERON PHARMA INC | $57,993,000 | +22.8% | 1,553,937 | 0.0% | 7.55% | +33.6% | |
| DERM | Buy | DERMIRA INC | $51,883,000 | +16.0% | 1,921,580 | +25.2% | 6.75% | +26.2% |
| CRVS | CORVUS PHARMACEUTICALS INC | $51,710,000 | +31.7% | 3,244,046 | 0.0% | 6.73% | +43.3% | |
| ANAB | Sell | ANAPTYSBIO INC | $41,612,000 | -42.7% | 1,190,604 | -60.8% | 5.42% | -37.6% |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $37,128,000 | +42.4% | 1,887,535 | +4.0% | 4.83% | +54.9% |
| FLXN | FLEXION THERAPEUTICS INC | $36,270,000 | +19.6% | 1,500,000 | 0.0% | 4.72% | +30.1% | |
| RARX | RA PHARMACEUTICALS INC | $29,661,000 | -22.1% | 2,031,562 | 0.0% | 3.86% | -15.3% | |
| MRUS | MERUS N V | $28,025,000 | +25.4% | 1,410,417 | 0.0% | 3.65% | +36.4% | |
| Buy | NABRIVA THERAPEUTICS PLC | $23,782,000 | -2.5% | 2,903,800 | +24.8% | 3.10% | +6.1% | |
| RETA | REATA PHARMACEUTICALS INCcl a | $18,436,000 | -1.7% | 592,794 | 0.0% | 2.40% | +6.9% | |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $18,341,000 | -14.1% | 2,725,283 | -6.1% | 2.39% | -6.6% |
| IVTY | INVUITY INC | $12,138,000 | +22.8% | 1,363,848 | 0.0% | 1.58% | +33.6% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $11,370,000 | +31.6% | 740,740 | 0.0% | 1.48% | +43.3% | |
| WMGIZ | WRIGHT MED GROUP N Vright 03/01/2019 | $7,164,000 | +6.2% | 4,622,032 | 0.0% | 0.93% | +15.5% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $3,991,000 | +11.5% | 223,317 | 0.0% | 0.52% | +21.3% | |
| APEN | Sell | APOLLO ENDOSURGERY INC | $1,285,000 | -88.0% | 274,472 | -79.7% | 0.17% | -86.9% |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -127,563 | -100.0% | -0.05% | – |
| HTGM | Exit | HTG MOLECULAR DIAGNOSTICS INC | $0 | – | -1,230,399 | -100.0% | -0.39% | – |
| OBSV | Exit | OBSEVA SA | $0 | – | -2,710,760 | -100.0% | -2.77% | – |
| SPNC | Exit | SPECTRANETICS CORP | $0 | – | -1,187,917 | -100.0% | -5.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.